第一医药(600833) - 2016 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders increased by 28.05% to CNY 41,583,966.97 year-on-year[7] - Operating income rose by 1.28% to CNY 1,154,483,236.86 for the first nine months[7] - Basic earnings per share increased by 28.02% to CNY 0.1864[7] - Net profit for the first nine months of 2016 reached CNY 41,583,966.97, representing a 28.2% increase from CNY 32,473,784.70 in the same period last year[21] - Operating profit for Q3 2016 was CNY 19,917,478.53, up 95.5% from CNY 10,222,046.13 in Q3 2015[21] - The company’s total profit for Q3 2016 was CNY 21,348,662.51, an increase of 73.1% from CNY 12,335,822.42 in Q3 2015[21] - Earnings per share for Q3 2016 were CNY 0.0783, compared to CNY 0.0416 in Q3 2015, reflecting a 88.5% increase[21] Asset and Liability Changes - Total assets decreased by 5.86% to CNY 1,157,990,956.61 compared to the end of the previous year[7] - Total current assets increased to ¥642,339,470.15 from ¥604,324,503.02, representing a growth of approximately 5.3%[14] - Total liabilities decreased to ¥425,127,173.79 from ¥447,043,748.28, a reduction of about 4.9%[15] - Owner's equity totaled ¥732,863,782.82, down from ¥783,090,933.55, showing a decrease of approximately 6.4%[15] - Non-current assets decreased to ¥515,651,486.46 from ¥625,810,178.81, a decline of approximately 17.6%[14] - Total assets decreased to ¥1,157,990,956.61 from ¥1,230,134,681.83, reflecting a decrease of about 5.9%[15] Cash Flow Analysis - Cash flow from operating activities decreased by 8.86% to CNY 50,661,363.32 compared to the same period last year[7] - The total cash inflow from operating activities for the first nine months of 2016 was CNY 1,223,728,033.94, a slight increase from CNY 1,208,347,683.58 in the same period last year, representing a growth of approximately 1.7%[24] - The net cash flow from operating activities decreased to CNY 50,661,363.32 from CNY 55,586,235.16, reflecting a decline of about 8.2% year-over-year[24] - The cash inflow from investment activities increased significantly to CNY 7,162,358.84, compared to CNY 3,958,038.09 in the previous year, marking an increase of approximately 81.5%[24] - The net cash flow from investment activities was CNY 5,545,778.93, up from CNY 1,805,925.38, indicating a growth of about 206.5% year-over-year[24] - The net cash outflow from financing activities was CNY -13,383,564.76, worsening from CNY -11,073,014.40, which is a decline of approximately 20.9%[24] - The total cash and cash equivalents at the end of the reporting period amounted to CNY 242,388,244.52, an increase from CNY 209,342,991.64, representing a growth of about 15.8%[24] Shareholder Information - The number of shareholders reached 19,407 at the end of the reporting period[10] Investment Income - Investment income rose by 84.78% to CNY 7,122,203.06 compared to the same period last year[11] - The company recorded an investment income of CNY 6,916,958.00 in Q3 2016, significantly higher than CNY 44,205.15 in Q3 2015[21] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[21]